Results from a new study out of France suggests that progression-free survival (PFS) rate may be significantly higher in cancer patients treated with targeted therapies when they employed a multigene panel test on their tumor samples compared with the PFS in these patients when they were treated with previous line of therapy. Writing in the journal Cancer Discovery, researchers report on findings from a prospective trial that included 1035 adults, and biopsy obtained from 948 of them.1

In this trial, all the patients had advanced, unresectable, or metastatic cancer that had progressed after at least 1 line of prior therapy. The researchers found there was an actionable molecular alteration identified in 411 of 843 patients with a molecular profile. In this cohort, 199 patients were treated with a targeted therapy matched to their genomic alteration, explained the researchers

Following targeted therapy, 2 of the evaluable patients had complete responses and 20 had partial responses, for an overall response rate of 11%. The study also demonstrated 100 patients had stable disease and 33 patients had progressive disease. The median overall survival was 11.9 months. The authors concluded that high-throughput genomics could help improve outcomes in a subset of patients with hard-to-treat cancers. 

Reference

1. Massard C, Michiels S, Ferté C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov. 2017 April. doi: 10.1158/2159-8290.CD-16-1396 [Epub ahead of print]